Sun Pharmaceutical Industries reported robust consolidated financial results for Q4 FY26, showcasing significant profit and revenue growth, even as its crucial US generics business continues to face ...

WASHINGTON, May 18 (Reuters) - U.S. President Donald Trump said on Monday that TrumpRx.gov, a government-backed website that lists discounted prescription drugs, will begin featuring generic medicines ...

Patent expiry across API, formulation, and device IP is expected to catalyze biosimilar competition, expanding access while compressing pricing across pharmaceutical and device value chains.

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

The most significant addition to the Java language since Sun Microsystems rewrote the collections API for Java 5 is the introduction of Java records. Java records address two significant pain points ...

Java is an object-oriented programming language. To create objects and meaningfully initialize them, a developer must use a Java constructor. Constructors are a critical part of software development ...

John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. Lizzy leads STAT’s coverage of the ...

Novo Nordisk is leaning on clinical evidence, localised pricing and partnerships as its frontline defence in India’s brutal semaglutide price war unleashed after the Danish company’s patent expired on ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Dany Lepage discusses the architectural ...

Over the last year, Sanofi has been busy reshaping itself to focus more on innovative drugs, including selling a controlling stake in its former consumer business and using those proceeds to strike a ...

A revolution is coming in the U.S. generics marketplace, one that has the potential to transform savvy organizations into engines of growth, and to end the decades-long “race to the bottom” that for ...